Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mild-to-moderate Alzheimer's Disease AND ALZHEIMER Disease AND MRI

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: Mild-to-moderate Alzheimer's Disease AND ALZHEIMER Disease AND MRI. Displaying page 3 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2015-005263-16 Sponsor Protocol Number: NSC15001 Start Date*: 2016-07-11
    Sponsor Name:Pharmatrophix Inc
    Full Title: A 6-months prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate safety, tolerability and exploratory endpoints of either placebo or two d...
    Medical condition: Mild to moderate Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    20.0 100000004852 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004944-31 Sponsor Protocol Number: EVE-AT-0412 Start Date*: 2014-06-27
    Sponsor Name:EVER Neuro Pharma GmbH
    Full Title: Comparison of Cerebrolysin and donepezil: A randomized, double-blind, controlled trial on efficacy and safety in patients with mild to moderate Alzheimer’s disease
    Medical condition: Mild to moderate dementia of Alzheimer type (DAT)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10012292 Dementia of the Alzheimer's type NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-003435-31 Sponsor Protocol Number: CL-758010 Start Date*: 2006-02-03
    Sponsor Name:Neurochem Inc.
    Full Title: A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.
    Medical condition: Alzheimer’s Disease (AD) is an irreversible, progressive neuro-degenartive disorder, characterized by gradual cognitive deficits associated with abnormal behaviour, personality changes, and which u...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) BE (Completed) SE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001755-41 Sponsor Protocol Number: GV971-007 Start Date*: 2021-02-10
    Sponsor Name:Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
    Full Title: A Phase 3, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of sodium oligomannate (GV-971) in treatment of mild to mode...
    Medical condition: mild to moderate Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012614-48 Sponsor Protocol Number: H3B110651 Start Date*: 2009-10-26
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the H3 receptor antagonist, GSK239512 in subjects with mild to moderate Alzheimer’s disease.
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-008005-21 Sponsor Protocol Number: DIM18 Start Date*: 2009-07-28
    Sponsor Name:Medivation, Inc.
    Full Title: CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease on Donep...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) FI (Completed) FR (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005118-37 Sponsor Protocol Number: H6L-MC-LFAN (e) Start Date*: 2008-12-15
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo
    Medical condition: Alzheimers Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Completed) FI (Completed) ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) GR (Prematurely Ended) SE (Prematurely Ended) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002957-37 Sponsor Protocol Number: RVT-101-3001 Start Date*: 2016-04-22
    Sponsor Name:Axovant Sciences Ltd.
    Full Title: A Phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) CZ (Completed) SK (Completed) ES (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010067-16 Sponsor Protocol Number: CN156018 Start Date*: 2009-07-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal ...
    Medical condition: ALZHEIMER DISEASE
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000217-30 Sponsor Protocol Number: 3098012 Start Date*: 2015-06-16
    Sponsor Name:Orion Corporation
    Full Title: EFFICACY OF ORM-12741 ON AGITATION/AGGRESSION SYMPTOMS IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE STUDY OF 12 WEEKS
    Medical condition: The agitation/aggression symptoms in patients with Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FI (Completed) PL (Completed) BG (Completed) RO (Suspended by CA) HR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010922-21 Sponsor Protocol Number: B2571007(3134K1-2203-EU) Start Date*: 2009-09-18
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
    Full Title: A phase II a , Multicenter, Randomized , Third -party Unblinded , Long- term Extension study to Determine Safety, Tolerability and Immunogenicity of ACC-001 with QS-21 Adjuvant in Subjects with Mil...
    Medical condition: Patients with mild to moderate Alzheimer's disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002653-30 Sponsor Protocol Number: EVP-6124-025 Start Date*: 2014-03-18
    Sponsor Name:EnVivo Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer’s Disease Currently or Previou...
    Medical condition: Mild to moderate Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    16.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001477-94 Sponsor Protocol Number: 3098B1-203 Start Date*: 2006-05-08
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S...
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002780-27 Sponsor Protocol Number: GAL-ALZ-3005 Start Date*: 2008-08-26
    Sponsor Name:Janssen Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-severe Alzheimer’s Disease
    Medical condition: Mild to moderately severe Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) LT (Completed) LV (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-007926-21 Sponsor Protocol Number: H8A-MC-LZAN(b) Start Date*: 2009-08-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of Passive Immunization on the Progression of Alzheimer’s Disease: LY2062430 versus Placebo
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002758-39 Sponsor Protocol Number: H6L-MC-LFBC (c) Start Date*: 2009-03-03
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of LY450139, a γ-Secretase Inhibitor, on the Progression of Alzheimer’s Disease as Compared with Placebo
    Medical condition: Alzheimers Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) PT (Prematurely Ended) BG (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000830-42 Sponsor Protocol Number: B2081011 Start Date*: 2014-10-23
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017
    Full Title: A Randomized, 18-Week, Placebo Controlled, Double Blind, Parallel Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) in Subjects with Mild to Moderate Alzheimer's Disease with Existing...
    Medical condition: Mild-to-Moderate Alzheimer's Disease with extising Nueropsychiatric Symptoms
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002618-10 Sponsor Protocol Number: EVP-6124-024 Start Date*: 2014-02-18
    Sponsor Name:EnVivo Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer’s Disease Currently or Previou...
    Medical condition: Mild to moderate Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    16.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000080-43 Sponsor Protocol Number: REMAD-02 Start Date*: 2022-08-04
    Sponsor Name:reMYND
    Full Title: A randomized, placebo-controlled, double-blind, parallel-group Phase 2a exploratory study with placebo run-in to investigate PK/PD effects, safety, tolerability and pharmacokinetics of REM0046127 o...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005994-79 Sponsor Protocol Number: 3133K1-3000-WW Start Date*: 2008-05-13
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co...
    Medical condition: Enfermedad de Alzheimer Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 21 17:03:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA